• Microbiology

    • Gram-negative, obligate anaerobic bacillus (rod-shaped).
    • Normal commensal of the human colon, comprising a large portion of the gut microbiota.
    • Appears pleomorphic (variable in shape) and may have vacuoles.
    • Aerotolerant, meaning it can survive in the presence of low oxygen concentrations due to enzymes like catalase and superoxide dismutase.
  • Pathophysiology/Etiology

    • An opportunistic pathogen that causes infection when the mucosal barrier of the GI tract is disrupted (e.g., surgery, trauma, diverticulitis, malignancy).
    • Infections are typically polymicrobial, involving other anaerobes and facultative aerobes (e.g., E. coli).
    • Virulence Factors:
      • Polysaccharide capsule: Antiphagocytic and a key factor for abscess formation.
      • Lipopolysaccharide (LPS): Has low endotoxic activity compared to other gram-negative bacteria, resulting in less severe septic shock.
      • Succinic acid production: Inhibits neutrophil function.
      • Enterotoxigenic B. fragilis (ETBF): Strains that produce B. fragilis toxin (BFT), a metalloprotease that can cause inflammatory diarrhea.
  • Clinical Presentation

    • Most common cause of intra-abdominal infections (e.g., peritonitis, abscesses) following a breach of the intestinal wall.
    • Clinical signs often include fever, abdominal pain, and abscess formation.
    • Infections are often associated with a foul-smelling discharge due to anaerobic metabolism.
    • Can cause infections at other sites, including:
      • Diabetic foot ulcers and other skin/soft tissue infections.
      • Pelvic inflammatory disease (PID) and tubo-ovarian abscesses.
      • Bacteremia, which is associated with significant mortality.
  • Diagnosis

    • Dx is often clinical, based on the setting of recent surgery, trauma, or underlying GI disease.
    • Anaerobic culture from a normally sterile site (e.g., abscess aspirate, blood) is the gold standard. Wound swabs have low diagnostic yield due to contamination.
    • Imaging (e.g., CT scan) is crucial to identify and locate abscesses for drainage.
  • Management/Treatment

    • Source control is critical: drainage of abscesses and debridement of necrotic tissue.
    • Antibiotic therapy:
      • Intrinsically resistant to penicillins via β-lactamase production.
      • High rates of resistance to clindamycin.
      • Effective agents include:
        • Metronidazole (drug of choice for anaerobes).
        • β-lactam/β-lactamase inhibitor combinations (e.g., Piperacillin-tazobactam, Ampicillin-sulbactam).
        • Carbapenems (e.g., Imipenem, Meropenem).
      • Empiric therapy for intra-abdominal infections must cover both anaerobes and Enterobacteriaceae.
  • Key Associations/Complications

    • Abscess formation is the hallmark of B. fragilis infection.
    • Post-operative infections, particularly after abdominal surgery.
    • Diabetic foot infections.
    • Potential association between enterotoxigenic B. fragilis (ETBF) and inflammatory bowel disease (IBD) flare-ups and colorectal cancer.